Positron Appoints New Management

NIAGARA FALLS, N.Y., Sept. 27, 2018 /PRNewswire/ -- Positron Corporation (OTC:POSC)(the “Company”), a nuclear medicine healthcare company, announces the appointment of Adel Abdullah as its President. Mr. Abdullah will also serve as a Director of the Board. Mr. Abdullah will lead the Company in its strategic plan and long term objectives moving forward. Adel Abdullah has been instrumental to Positron’s ability to deliver world class PET imaging technology, clinical & technical services to customers for over 10 years and will continue to do so for Positron’s customers.

Positron is also pleased to announce the appointment of Aaron Hargrave, Positron’s Director of Clinical Applications as Vice President. Mr. Hargrave is a Certified Nuclear Medicine Technologist, performing PET imaging in cardiac, oncology and neurologic subsets for Positron since 2010. Mr. Hargrave provides clinical and software support and training for Positron’s Attrius PET customers specializing in image quality and interpreting technical data, ensuring proper product use for optimal patient outcomes.

Mr. Abdullah and Mr. Hargrave have delivered top performing PET technology used in over 50,000 cardiac studies on Positron imaging systems.

Mr. Abdullah stated, “It is an exciting time at Positron. As a company we are on a new path that I expect will have great impact in the growth of the cardiac PET industry. Positron is stronger than ever with the ability to focus exclusively on its imaging technology, clinical services and innovative pro-business structures for its customers. Our goal is to work with champions of the cardiac PET industry to advance the adoption of cardiac PET utilizing Positron’s PET imaging systems and services.”

About Positron: Positron Corporation is a nuclear medicine healthcare company providing innovative PET technologies and practice solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services and solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes, while practicing cost effective medicine. Positron has made continues their strong commitment to excellence and advancing cardiac imaging solutions. Positron’s unique products, market position and approach in facilitating the adoption of cardiac PET to customers are substantial advantages to the growth of nuclear cardiology and Positron. Positron is redefining the industry.

More information about Positron is available at (317) 576-0183 or www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as “Risk Factors” in our filings with the Securities and Exchange Commission.

View original content:http://www.prnewswire.com/news-releases/positron-appoints-new-management-300719581.html

SOURCE Positron Corporation

Company Codes: OTC-PINK:POSC, OTC-QX:POSC